CollPlant Biotechnologies
CLGN
21 hedge funds and large institutions have $10.7M invested in CollPlant Biotechnologies in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
5% more funds holding
Funds holding: 20 → 21 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.51% less ownership
Funds ownership: 15.78% → 14.27% (-1.5%)
25% less capital invested
Capital invested by funds: $14.3M → $10.7M (-$3.61M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $3K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IMOV
Investment Management of Virginia
Richmond,
Virginia
|
+$463K |
| 2 |
SDJVC
St. Denis J. Villere & Co
New Orleans,
Louisiana
|
+$157K |
| 3 |
Jane Street
New York
|
+$108K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$38.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$13.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$2.19M |
| 2 |
LPL Financial
San Diego,
California
|
-$138K |
| 3 |
BFEC
Benjamin F. Edwards & Company
St. Louis,
Missouri
|
-$51.9K |
| 4 |
Brown Advisory
Baltimore,
Maryland
|
-$28.4K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$7K |
CLGN Hedge Fund Activity: Q3 2022 in Review
21 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in CollPlant Biotechnologies (CLGN) for Q3 2022, worth a combined $10.7M — down 25% from $14.3M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CLGN positions and 3 closed out — a net gain of 1 holder — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Investment Management of Virginia, adding an estimated $463K. The largest seller was ARK Investment Management, exiting entirely with an estimated $2.19M sold.
- 21 institutional investors held CollPlant Biotechnologies (CLGN) as of Q3 2022, up from 20 in Q2 2022.
- Funds reported $10.7M of CollPlant Biotechnologies stock for Q3 2022, down 25% quarter-over-quarter.
- 4 funds opened new CollPlant Biotechnologies positions in Q3 2022 and 3 closed out, a net change of +1 holder.
- The largest CollPlant Biotechnologies buyer in Q3 2022 was Investment Management of Virginia, an estimated $463K added.
- The largest CollPlant Biotechnologies seller in Q3 2022 was ARK Investment Management, an estimated $2.19M sold.
Based on aggregated 13F filings for Q3 2022.